US and UK Announce Duty-Free Pact on Pharmaceuticals.
Britain and America have reached a major commercial pact that will keep zero duties on UK pharmaceutical shipments being sold in the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has pledged to boost expenditure on drugs through the National Health Service (NHS). This commitment secures that duties on these key exports will be held at zero for a period of three years.
This agreement comes after recent warnings to significantly raise duties on patented drug imports, with increases floated up to double the cost.
"This agreement with the Britain reinforces the international landscape for new treatments and brings much-needed fairness to U.S.–U.K. pharmaceutical trade," a release noted.
Commercial Significance
Drugs are one of the the United Kingdom's largest exports to the United States, which is clearly the largest market for major UK drugmakers.
Export figures indicate that in the year prior to September, the UK sold drugs valued at over eleven billion pounds to the US. This figure represented a significant portion of total UK exports in that period.
"This guarantee safeguards work, boosts investment and facilitates the UK to establish itself as a worldwide center for life sciences," a government official commented.
Detailed NHS Changes
The agreement involves several specific changes from the British government:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to raise total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to stay within budget will be limited at 15%. Last year, refunds exceeded twenty percent.
Recent Tensions
The deal takes place against a ongoing dispute between the drug companies and the British authorities over spending levels and NHS adoption.
These tensions were intensified by claims that US patients were paying several times more for the identical medicines than consumers in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar investments have been announced toward American operations.
A senior figure acknowledged that the NHS had to increase expenditure on drugs, noting that its spending on drugs had declined as a proportion of its resources over the last ten years.
